Molecular Partners (OTCMKTS:MLLCF – Get Free Report) will likely be posting its results before the market opens on Tuesday, August 25th. Analysts expect Molecular Partners to post earnings of ($0.4330) per share for the quarter.
Molecular Partners Price Performance
Molecular Partners stock opened at $3.80 on Friday. The stock has a 50-day simple moving average of $3.89 and a 200 day simple moving average of $3.14. Molecular Partners has a 12-month low of $2.25 and a 12-month high of $4.85.
Molecular Partners Company Profile
Molecular Partners AG is a clinical-stage biotechnology company headquartered in Zurich, Switzerland, specializing in the development of novel protein therapeutics based on its proprietary DARPin® (Designed Ankyrin Repeat Proteins) platform. The company’s pipeline focuses on precision molecules engineered for oncology and immuno-inflammatory diseases, as well as antiviral and anti-infective applications. By leveraging the modular nature of DARPin® science, Molecular Partners designs small, highly stable binding proteins that can engage multiple targets simultaneously, potentially improving efficacy and safety profiles over conventional antibody approaches.
Founded in 2004 by Professor Andreas Plückthun at the University of Zurich, Molecular Partners has advanced several clinical-stage candidates through Phase 1 and Phase 2 trials.
Recommended Stories
- Five stocks we like better than Molecular Partners
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
